Intuitive Surgical Inc (ISRG) Stock AnalysisISRGIntuitive Surgical Inc

Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Intuitive Surgical Inc is a good buy right now due to its strong revenue growth, with a 21% year-over-year increase in FY 2025, and a current price of $426.70, which is below several analyst price targets, including $454 from BTIG and $485 from Barclays. The RSI of 67.29 indicates strong momentum, while the forward P/E of 33.33 suggests growth potential despite current market volatility. However, the main risk is the intense competition in the surgical robotics market, particularly from Medtronic and Johnson & Johnson, which could impact future earnings.

17 analysts cover ISRG: 11 rate it Buy, 5 Hold and 1 Sell. The average price target is 637.32.